CORD-19:ee0a7632371a08727d41e55aad7d621daeceef7d / 112296-112457 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T94870","span":{"begin":0,"end":161},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Replacement of FLT3 mutations with NRAS mutations in patients on FLT3 inhibitors is suggestive of AML dependence on mutations in these kinase-signaling pathways."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T227","span":{"begin":0,"end":161},"obj":"Sentence"}],"text":"Replacement of FLT3 mutations with NRAS mutations in patients on FLT3 inhibitors is suggestive of AML dependence on mutations in these kinase-signaling pathways."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T254","span":{"begin":98,"end":101},"obj":"Phenotype"}],"attributes":[{"id":"A254","pred":"hp_id","subj":"T254","obj":"http://purl.obolibrary.org/obo/HP_0004808"}],"text":"Replacement of FLT3 mutations with NRAS mutations in patients on FLT3 inhibitors is suggestive of AML dependence on mutations in these kinase-signaling pathways."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T616","span":{"begin":98,"end":101},"obj":"Disease"},{"id":"T615","span":{"begin":98,"end":101},"obj":"Disease"}],"attributes":[{"id":"A616","pred":"mondo_id","subj":"T616","obj":"http://purl.obolibrary.org/obo/MONDO_0018874"},{"id":"A617","pred":"mondo_id","subj":"T616","obj":"http://purl.obolibrary.org/obo/MONDO_0015667"},{"id":"A72937","pred":"mondo_id","subj":"T615","obj":"http://purl.obolibrary.org/obo/MONDO_0018874"},{"id":"A9862","pred":"mondo_id","subj":"T615","obj":"http://purl.obolibrary.org/obo/MONDO_0015667"}],"text":"Replacement of FLT3 mutations with NRAS mutations in patients on FLT3 inhibitors is suggestive of AML dependence on mutations in these kinase-signaling pathways."}